GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artelo Biosciences Inc (NAS:ARTL) » Definitions » Total Current Liabilities

ARTL (Artelo Biosciences) Total Current Liabilities : $1.77 Mil (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Artelo Biosciences Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Artelo Biosciences's total current liabilities for the quarter that ended in Dec. 2024 was $1.77

Artelo Biosciences Total Current Liabilities Historical Data

The historical data trend for Artelo Biosciences's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artelo Biosciences Total Current Liabilities Chart

Artelo Biosciences Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23 Dec24
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.50 0.53 1.00 1.29 1.77

Artelo Biosciences Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.29 0.72 0.94 0.70 1.77

Artelo Biosciences Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Artelo Biosciences's Total Current Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1.74+0.035
+Other Current Liabilities+Current Deferred Liabilities
=-0.0029999999999999+0
=1.77

Artelo Biosciences's Total Current Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1.74+0.035
+Other Current Liabilities+Current Deferred Liabilities
=-0.0029999999999999+0
=1.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Artelo Biosciences Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Artelo Biosciences's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Artelo Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artelo Biosciences Inc (NAS:ARTL) » Definitions » Total Current Liabilities
Comparable Companies
ENVB MTNB LIXT TTNP NBY VIVS NCNA PALI GLMD SNPX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
505 Lomas Santa Fe, Suite 160, Solana Beach, CA, USA, 92075
Website
https://www.artelobio.com
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Executives
Gregory D. Gorgas director, officer: See Remarks 888 PROSPECT, SUITE 210, LA JOLLA CA 92037
Tamara A Seymour director C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008
Gregory Reyes director 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922
Matsui Connie director 3030 CALLAN RD, SAN DIEGO CA 92121
John W Beck director C/O RITTER PHARMACEUTICALS, INC., 1880 CENTURY PARK EAST, SUITE 1000, LOS ANGELES CA 90067
Robert Martin Emanuele director
David J Moss 10 percent owner C/O PEGASI ENERGY RESOURCES CORPORATION, 218 N. BROADWAY, SUITE 204, TYLER TX 75702
Georgia Erbez director 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Steven Kelly director C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Douglas Blayney director C/O ARTELO BIOSCIENCES, INC., 888 PROSPECT ST, SUITE 210, LA JOLLA CA 92037
Peter Michael O'brien 10 percent owner C/O ARTELO BIOSCIENCES, INC., 888 PROSPECT ST, SUITE 210, LA JOLLA CA 92037